Journal
NATURE REVIEWS CANCER
Volume 17, Issue 4, Pages 223-238Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc.2017.7
Keywords
-
Categories
Funding
- University of Cambridge (UK)
- Cancer Research UK [A11906, A20240, A15601]
- European Research Council (ERC) under the European Union [337905]
- Hutchison Whampoa Limited (Hong Kong)
- AstraZeneca (UK)
- Cambridge Experimental Cancer Medicine Centre
- National Institute for Health Research Biomedical Research Centre (UK)
- Spanish Society of Medical Oncology (SEOM)
- Cancer Research UK [15601, 16942, 20240] Funding Source: researchfish
- Healthway
- Cancer Research UK [22905] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0515-10090, NF-SI-0611-10154] Funding Source: researchfish
- European Research Council (ERC) [337905] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Improvements in genomic and molecular methods are expanding the range of potential applications for circulating tumour DNA (ctDNA), both in a research setting and as a `liquid biopsy' for cancer management. Proof-of-principle studies have demonstrated the translational potential of ctDNA for prognostication, molecular profiling and monitoring. The field is now in an exciting transitional period in which ctDNA analysis is beginning to be applied clinically, although there is still much to learn about the biology of cell-free DNA. This is an opportune time to appraise potential approaches to ctDNA analysis, and to consider their applications in personalized oncology and in cancer research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available